Rare Daily Staff
Emmes, a global, full-service Clinical Research Organization said that it has acquired rare disease focused CRO Orphan Reach.
The acquisition of UK-based Orphan Reach is Emmes’ second acquisition in the past four months. It follows the acquisition of Neox, an EU-based CRO, in December 2020. Neox and Orphan Reach expand Emmes’ global reach with their international footprints and add a larger and more diverse set of biopharmaceutical clients.
“Our acquisition of Orphan Reach will accelerate our growth, establishing us as an industry leader in clinical research for orphan and rare diseases,” said Emmes CEO Christine Dingivan. “Orphan Reach has an outstanding reputation, with experience in 60 rare disease clinical trials and over 50 biopharma clients throughout the world.”
The companies did not disclose financial terms of the acquisition.